In addition, fewer drug-drug interactions occur with gabapentin compared to either carbamazepine or valproic acid. Not enough data exist to compare the adverse-effect profiles of these agents when ...

Several recent studies have elucidated the benefits of GLP-1 therapies outside of weight loss, pointing to potential areas of expansion. GSK opened JPM25 with a $1.1 billion acquisition of IDRx and ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Click to share on X (Opens in new window) Click to share on LinkedIn (Opens in new window) Click to share on Facebook (Opens in new window) Click to share on Reddit (Opens in new window) Click to ...

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

However, GSK noted that IDRx's experimental therapy - IDRX-42 - was showing signs of preventing tumours from growing. The US Food and Drug Administration recently gave IDRX-42 fast-track ...

But Miels said the toxicity levels associated with the drug, which leads to about 43% of patients experiencing grade 3 or greater toxicity, are a driving part of GSK’s interest in IDRx.

GSK fired the opening gun for the 2025 JP Morgan Healthcare Conference on Monday with a front-loaded acquisition agreement, moving to buy precision therapy specialist IDRx and its rare cancer drug ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...